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Oxidative stress is closely associated with the pathophysiology of diabetic cardiomyopathy (DCM). The
mitochondrial ﬂavoenzyme monoamine oxidase A (MAO-A) is an important source of oxidative stress in
the myocardium. We sought to determine whether MAO-A plays a major role in modulating DCM.
Diabetes was induced in Wistar rats by single intraperitoneal injection of streptozotocin (STZ). To in-
vestigate the role of MAO-A in the development of pathophysiological features of DCM, hyperglycemic
and age-matched control rats were treated with or without the MAO-A-speciﬁc inhibitor clorgyline (CLG)
at 1 mg/kg/day for 8 weeks. Diabetes upregulated MAO-A activity; elevated markers of oxidative stress
such as cardiac lipid peroxidation, superoxide dismutase activity, and UCP3 protein expression; en-
hanced apoptotic cell death; and increased ﬁbrosis. All these parameters were signiﬁcantly attenuated by
CLG treatment. In addition, treatment with CLG substantially prevented diabetes-induced cardiac con-
tractile dysfunction as evidenced by decreased QRS, QT, and corrected QT intervals, measured by ECG,
and LV systolic and LV end-diastolic pressure measured by microtip pressure transducer. These beneﬁcial
effects of CLG were seen despite the persistent hyperglycemic and hyperlipidemic environments in STZ-
induced experimental diabetes. In summary, this study provides strong evidence that MAO-A is an im-
portant source of oxidative stress in the heart and that MAO-A-derived reactive oxygen species con-
tribute to DCM.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Diabetic cardiomyopathy (DCM) carries a substantial risk con-
cerning the subsequent development of heart failure and in-
creased mortality in diabetic patients [1]. It is characterized by
early diastolic dysfunction, accompanied by cardiomyocyte apop-
tosis, compensatory hypertrophy, and reparative ﬁbrosis [2]. Al-
though the features of diabetic cardiomyopathy have been well
identiﬁed, comprehensive understanding of the mechanismsInc. This is an open access article u
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.underlying the myocardial remodeling process is urgently needed.
Oxidative stress has been widely implicated in diabetes and its
many complications [3]. The heart is particularly susceptible to
oxidative damage, as it possesses lower levels of free radical sca-
vengers in comparison to other organs [4]. Increased levels of
cardiac lipid peroxidation and activity of antioxidant enzymes
such as catalase and superoxide dismutase seem to be relevant
with respect to oxidative stress in diabetes [5,6]. Experimental
models have allowed a better understanding of how oxidative
stress causes myocardial apoptosis and activates a series of cardiac
remodeling responses, leading to morphological and functional
abnormalities and eventually to cardiomyopathy [7]. In vivo stu-
dies demonstrated that diabetes-induced cardiac remodeling and
dysfunction can be reduced by targeting ROS with oral or systemic
antioxidant administration [5,8]. However, the precise sources of
ROS in the myocardium under diabetic conditions are unknown.
Monoamine oxidases (MAOs) are mitochondrial ﬂavoproteins
responsible for oxidation of monoamines. During this process they
generate H2O2 and reactive aldehydes as by-products. Based onnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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have been identiﬁed, MAO-A and MAO B. However, MAO-A ap-
pears to be the predominant isoform in the myocardium of several
species [9]. Recent ﬁndings demonstrate that pharmacological or
genetic inhibition of MAO-A prevents maladaptive remodeling and
left-ventricular dysfunction in mouse hearts subjected to pressure
overload [10]. Overexpression of MAO-A in mouse heart causes
oxidative stress-mediated mitochondrial damage and cardiomyo-
cyte necrosis, leading to ventricular dysfunction [11]. Moreover the
important role of MAO as a relevant source of ROS in ischemia/
reperfusion (I/R) injury was demonstrated both ex vivo [12] and
in vivo [13,14]. Yet the involvement of MAO-A in diabetic cardio-
myopathy is not deﬁned.
Therefore, we aimed to investigate whether MAO-A can po-
tentially be a relevant source of ROS and contribute to the devel-
opment of diabetic cardiomyopathy. In the current study, we
found that MAO-A activity but not protein expression was sig-
niﬁcantly upregulated in the myocardium of diabetic rats. Further
we have shown that inhibition of myocardial MAO-A activity with
a MAO-A speciﬁc inhibitor, CLG, reduced cardiac oxidative stress,
apoptosis, and ﬁbrosis, thus preventing cardiac dysfunction in
streptozotocin (STZ)-induced diabetic rats.1. Materials and methods
1.1. Animals and treatments
All animal research was approved by the Institutional Animal
Ethics Committee at the National Centre for Cell Science (Pune,
India). Male Wistar rats were housed in a temperature-controlled
room under a 12-h light/dark circadian cycle with access to water
and food ad libitum. At 6–8 weeks of age, rats were in-
traperitoneally (ip) administered a single dose of STZ (Sigma–Al-
drich, St. Louis, MO, USA) at 55 mg/kg BW, dissolved in 0.1 mol/L
citrate buffer, pH 4.5. An equivalent volume of citrate buffer was
administered to the vehicle control group. On day 3 after STZ
treatment, whole-blood glucose obtained from the rat tail vein
was monitored using a glucometer (Contour; Bayer, USA). Strep-
tozotocin-treated rats with fasting blood glucose higher than
12 mmol/L were considered diabetic. The rats were allocated into
the following groups: rats that received only vehicle (control, n ¼
6), rats treated with CLG (CLG, n ¼ 6), STZ-induced diabetic rats
(STZ, n ¼ 9), and diabetic rats treated with CLG (STZ þ CLG, n ¼
8). CLG was administered using saline as vehicle (1 mg/kg/day, ip)
on 4th day after the initial STZ/citrate buffer injection for 8 weeks.
1.2. Assessment of electrocardiographic and hemodynamic changes
and left-ventricular contractile function
At the end of 8 weeks, the rats were weighed and anesthetized
using urethane (1 g/kg/ BW, ip). Urethane was selected as an an-
esthetic agent as its single dose induces long-term anesthesia and
analgesia with minimal cardiovascular and respiratory system
depression [15]. The right carotid artery was cannulated with a
microtip pressure transducer (SPR-320; Millar Instruments) con-
nected to an eight-channel PowerLab instrument via a bridge
ampliﬁer (ADInstruments, Colorado Springs, CO, USA). The pres-
sure-tip transducer catheter was then advanced into the left
ventricle for the evaluation of ventricular pressures. LV systolic
and end-diastolic pressures and the maximum rate of LV systolic
pressure rise and fall (7dp/dt) were monitored and recorded
using Chart 5.5 (ADInstruments).
ECG leads were recorded with surface electrodes (ADInstru-
ments). The mean value for each rat was obtained from four values
consisting of four consecutive cardiac cycles using LabChartsoftware (ADInstruments). Corrected QT (QTc) intervals were
analyzed for an evaluation independent of heart rate. QTc was
calculated with mean values and the Bazett formula (QTc ¼ QT
interval/√(RR interval) [16].
1.3. Collection of blood, serum, and hearts from rats
After the hemodynamic measurements were recorded, hearts
were excised surgically and blood was collected. After the removal
of heart, it was washed with chilled phosphate-buffered saline
(PBS) to clear out blood. The ventricular portions of the heart were
removed and snap-frozen in liquid nitrogen for further experi-
ments. For isolation of serum, the blood was allowed to clot at
room temperature for 10 to 15 min and then centrifuged for
10 min at 3000g; clear serum was obtained and stored at 80°C
until use.1.4. Blood analysis
Serum levels of total cholesterol, low-density lipoprotein (LDL),
high-density lipoprotein (HDL), and troponin I levels were ana-
lyzed using appropriate kits on an RA-50 semiautoanalyzer by
well-standardized methods. Serum insulin levels were measured
by enzyme-linked immunosorbent assay (Mercodia AB, Sweden).
1.5. Liver function tests
Quantitative estimation of serum glutamate pyruvate transa-
minase (SGPT) and serum glutamate oxaloacetate transaminase
(SGOT) was done using a speciﬁc kit (Erba Diagnostics Mannheim
GmbH, Germany) on an RA-50 semiautoanalyzer by well-stan-
dardized methods [17].
1.6. Measurement of myocardial lipid peroxidation and antioxidant
enzyme activity
To assess myocardial lipid peroxidation, myocardial 4-hydro-
xynonenal (4-HNE) and malondialdehyde (MDA) levels were
examined.
Immunoﬂuorescence staining was carried out for 4-HNE.
Hearts were embedded in Tissue-Plus OCT compound (Fisher Sci-
entiﬁc, USA). Cryosections, 8 mm in thickness, were cut with a
cryostat (Shandon Cryotome; SME Cryostat) at 20°C and trans-
ferred onto Superfrost Plus Gold microscope slides (Fisher Scien-
tiﬁc). Frozen heart sections were ﬁxed in 3.7% paraformaldehyde.
After nonspeciﬁc binding was blocked with 3% bovine serum al-
bumin, the sections were incubated with a rabbit polyclonal anti-
4-HNE antibody (Alpha Diagnostic International, USA), followed by
Alexa Fluor 594-conjugated goat anti-rabbit IgG antibody (In-
vitrogen, USA). Slides were then mounted and imaged in an
Olympus FluoView FV10i confocal laser scanning microscope. For
negative-control experiments, primary antibody was omitted.
Images were analyzed using computer-assisted image analysis
systems (ImageJ; National Institutes of Health (NIH)).
Quantiﬁcation of MDA as a dithiobarbituric acid adduct was
done using an HPLC–Vis method as described previously [18].
The levels of superoxide dismutase (SOD), catalase, and glu-
tathione peroxidase (GPx) enzyme activities were measured using
a SOD Assay Kit-WST (Sigma), Amplex Red Catalase Assay Kit
(Invitrogen), and Glutathione Peroxidase Activity Kit (Enzo Life
Sciences), respectively, according to the manufacturer’s instruc-
tions. Enzyme activities were normalized to protein concentration
in the samples.
Table 1
Physiological parameters of the experimental animals
Control CLG STZ STZ þ CLG
Body weight (g) 334.71 7 6.71 338.17 7 2.95 262.13 7 5nn 215.86 7 11.44
HW/BW (mg/g) 2.93 7 0.08 3.33 7 0.15 3.61 7 0.12nn 3.91 7 0.12
Serum insulin (ng/ml) 0.30 7 0.08 0.49 7 0.08 0.16 7 0.03nn 0.15 7 0.01
Blood glucose (mg/dl) 95.29 7 7.09 88.83 7 12.91 541.60 7
13.85nnn
550.71 7 9.57
Total cholesterol (mg/dl) 35.00 7 1.93 49.17 7 1.64 51.56 7 3.50nnn 49.14 7 1.22
HDL/LDL ratio 0.479 7 0.08 0.362 7 0.03 0.328 7 0.01n 0.346 7 0.01
Liver function test
SGPT (IU/L) 52.83 7 4.17 50.20 7 3.15 88.75 7 8.93n 97.29 7 7.92
SGOT (IU/L) 115.80 7 3.40 120.67 7 7.01 157.17 7 5.26n 152.13 7 17.13
Troponin I (biomarker of myocardial injury; ng/ml) 0.09 7 0.03 0.05 7 0.02 0.31 7 0.06nnn 0.09 7 0.03#
All values are given as mean 7 SE (n ¼ 6–8/group).
n p o 0.05 vs control group.
nn p o 0.01 vs control group.
nnn p o 0.001 vs control group.
# p o 0.05 vs STZ group.
Table 2
Hemodynamic and ECG interval measurements of the experimental animals
Control CLG STZ STZ þ CLG
ECG parameters
Heart rate (bpm) 239.88 7
8.71
305.41 7
12.75
199.15 7
7.97n
231.58 7
11.90
QRS interval (ms) 27.78 7
0.25
33.50 7
0.58
35.91 7
0.28nnn
33.50 7
1.12#
QT interval (ms) 139.58 7
5.12
110.90 7
1.59
177.27 7
7.59nn
152.46 7
5.41#
QTc (ms) 203.70 7
7.05
171.20 7
4.09
231.36 7
3.47n
204.03 7
5.21#
Hemodynamic parameters
MABP (mm Hg) 72.44 7
2.91
78.54 7
4.84
98.07 7
4.57n
62.96 7
7.56###
Systolic duration (s) 0.088 7
0.004
0.076 7
0.003
0.111 7
0.006nn
0.111 7
0.007 (ns)
Diastolic duration
(s)
0.165 7
0.006
0.125 7
0.008
0.193 7
0.008n
0.151 7
0.009#
Contractility index
(1/s)
10.43 7
0.60
9.41 7 0.37 7.06 7
0.45n
10.15 7 1.07#
bpm, beats per minute; MABP, mean arterial blood pressure. All values are given as
the mean 7 SE (n ¼ 4–8/group).
n p o 0.05 vs control group.
nn p o 0.01 vs control group.
nnn p o 0.001 vs control group.
# p o 0.05 vs STZ group.
### p o 0.001 vs STZ group.
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Ventricular tissues (50 mg) were homogenized on ice in 0.1 M
perchloric acid, 0.3 mM EDTA, and 107 M ascorbic acid. Homo-
genates were centrifuged at 4 °C, 12,000 rpm, for 5 min. The su-
pernatants were ﬁltered using 0.22-μm nylon disposable syringe
ﬁlters and stored at 80 °C until analyzed. Dihydroxybenzylamine
was used as an internal standard. Norepinephrine (NE) and dihy-
droxyphenylglycol (DHPG) were determined by HPLC as described
previously [19].
1.8. Determination of MAO-A activity assay
MAO-A activity was determined using the Amplex Red Mono-
amine Oxidase Assay Kit from Invitrogen. The assay was optimized
to measure MAO-A activity in heart tissue homogenates using
5-hydroxytryptamine (5-HT) as the enzymatic substrate. Forty
micrograms of heart tissue lysates were incubated for 1 h at 37 °C
with 2 mM 5-HT, 400 mmol Amplex red, and 2 U/ml horseradishperoxidase solution. The ﬂuorescence was measured in a ﬂuores-
cence microplate reader (Synergy HT; BioTek, USA) using excita-
tion in the range of 530/25 nm and emission detection at 590/
20 nm. Resoruﬁn was used to prepare a standard curve. MAO ac-
tivity was expressed as micromoles of resoruﬁn formed per mil-
ligram of protein per hour [20,21].
1.9. Estimation of caspase 3 and caspase 9 activity
Tissue homogenates were centrifuged (10,000 g at 4 °C, 10 min)
and pellets were lysed in an ice-cold cell lysis buffer (50 mM
HEPES, pH 7.4, 0.1% CHAPS, 100 mM NaCl, 1 mM dithiothreitol
(DTT), and 0.1 mM EDTA). The assay was carried out in a 96-well
plate with each well containing 10 μl cell lysate, 80 μl of assay
buffer (50 mM HEPES, pH 7.4, 0.1% CHAPS, 100 mM NaCl, 10 mM
DTT, 0.1 mM EDTA, and 10% glycerol), and 10 μl of caspase col-
orimetric substrate (2 mM). For measurement of caspase 3 and
9 activity, caspase 3 colorimetric substrate (Ac-DEVD-pNA; Cal-
biochem) and caspase 9 colorimetric substrate (Ac-LEHD-pNA;
Sigma) were used, respectively. The plate was incubated at 37 °C
for 1 h. Cleavage of the chromophore pNA from the substrate
molecule was monitored at 405 nm. Caspase 3 and 9 activities
were expressed as picomoles of pNA released per microgram of
protein per minute [22].
1.10. Histological examination of myocardial tissues
Heart ventricular portions were ﬁxed in 10% neutral-buffered
formalin. The specimens were embedded in parafﬁn and cut into
5-μm sections. Morphological changes were examined. Images of
hematoxylin and eosin (H&E)-stained sections were captured. In-
terstitial and perivascular ﬁbrosis was evaluated by Picrosirius red
staining. Sections were stained with 0.1% Sirius red F3BA and
0.25% fast green FCF for the collagen accumulation and observed
under a microscope (SONY, DSC-w530) at 200 magniﬁcation.
Photomicrographs of the sections were evaluated for collagen
fractions using computer-assisted image analysis systems (ImageJ;
NIH) as described in a previous study [23].
1.11. Tunel assay
For terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) assay, an in situ cell death detection kit
(Roche GmbH, Germany) was used according to the manu-
facturer’s instructions. Brieﬂy, the slides were deparafﬁnized and
rehydrated using xylene and ethanol gradings and permeabilized
Fig. 1. MAO-A inhibition prevents diabetes-induced cardiac dysfunction. (A) Left-ventricular systolic pressure, (B) left-ventricular end-diastolic pressure, (C) LV dp/dtmin
and (D) (LV dP/dtmin)/LVSP. All values are given as the mean 7 SE (n ¼ 5/group); *p o 0.05 vs control group; #p o 0.05, ###p o 0.001 vs STZ group.
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ture containing TdT and ﬂuorescein-labeled dUTP for 1 h at 37 °C.
Images were captured with a confocal laser scanning microscope
(Zeiss LSM510). For a negative control, TdT was omitted from the
reaction mixture. TUNEL-positive and 4′,6-diamidino-2-phenyl-
indole-stained nuclei were counted using the ImageJ software
(version 1.43r; NIH). At least 500 cells were counted in each ﬁeld
[22].
1.12. Western blot analysis
Heart tissues were rinsed with cold PBS and then homogenized
in RIPA buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1.0% NP-40,
1.0% Triton X-100, 0.1% SDS, 1% sodium deoxycholate, 10% glycerol,
1 mM EDTA, and protease inhibitor cocktail; Roche). Protein con-
centrations were determined by Bradford assay (Bio-Rad protein
assay kit). Equal amount of proteins (40 mg) were denatured in
SDS–PAGE sample buffer, resolved by SDS–PAGE, and transferred
to a polyvinylidene diﬂuoride membrane followed by blocking of
the membrane with 5% nonfat milk powder (w/v) in 10 mM Tris,
150 mM NaCl, 0.5% Tween 20. The membranes were incubated
with antibodies to Bax, Bcl-2, COX IV (1:1000; Santa Cruz Bio-
technology); cytochrome c (1:1000; Cell Signaling Technology);
UCP3 (1:1000; US Biological); MAO-A, peroxiredoxin 3 and 5
(1:1000; Abcam); or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; 1:1000; Sigma). followed by the appropriate horseradish
peroxidase-conjugated secondary antibodies and visualized by an
enhanced chemiluminescence (Pierce) detection system. Protein
levels were normalized to that of GAPDH.
For detection of cytochrome c release from mitochondria to
cytosol, protein extraction of the cytosolic fractions was performed
using a method as described previously with slight modiﬁcations
[24]. Brieﬂy, heart tissue was homogenized by gently douncing 30
times in a glass Dounce homogenizer in 7 volumes of coldsuspension buffer A (20 mM HEPES–KOH, pH 7.5, 250 mM sucrose,
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
17 mg/ml phenylmethanesulfonyl ﬂuoride, 2 mg/ml leupeptin, 8 mg/
ml aprotinin). Unlysed tissue and nuclei were pelleted via a 10-
min, 750 g spin. The supernatant was centrifuged at 10,000g for
25 min. This pellet was resuspended in buffer A and represents the
mitochondrial fraction. The supernatant was centrifuged at
100,000g for 1 h at 4 °C. The supernatant from this ﬁnal cen-
trifugation represents the soluble cytosolic fraction. We examined
possible cross-contamination by COX subunit IV as a mitochon-
drial and GAPDH as a cytosolic marker in both fractions.
1.13. Statistical analysis
Data are presented as the mean 7 SEM. Comparison between
groups was performed by one-way ANOVA, followed by a Tukey's
post hoc multiple comparison test, and comparisons between two
groups were performed using unpaired two-tailed Student t test
using Prism 4.0 GraphPad software (GraphPad, San Diego, CA,
USA). A value of p o 0.05 was considered signiﬁcant.2. Results
2.1. General effects of clorgyline on diabetic and control rats
STZ-administered rats showed characteristic symptoms of
diabetes, including polydipsia, polyuria, and increased food intake,
along with reduced body weight. Moreover, heart-to-body weight
ratio (HW/BW) in the STZ group was higher than in the vehicle
control group (p o 0.01). STZ-induced diabetes led to a decrease
in the serum insulin levels (p o 0.01) with concomitant increase
in blood glucose levels (p o 0.001).
After 8 weeks of diabetes, the STZ groups showed signiﬁcantly
Fig. 2. Diabetes induces myocardial MAO-A activity. (A) MAO-A protein expression. Representative Western blot image (left) and densitometric analysis (right; n ¼ 8/group).
(B) MAO-A activity (n ¼ 6–8/group) and (C) quantiﬁcation of DHPG/NE ratio by HPLC method (n ¼ 4/group). All values are given as the mean 7 SE; **p o 0.01, ***p o 0.001
vs control group; ##p o 0.01, ###p o 0.001 vs STZ group.
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o 0.001) and exhibited lower HDL/LDL ratio than the vehicle
control groups (p o 0.05). Serum biomarkers of liver damage,
SGPT and SGOT, were higher in diabetic rats compared to vehicle
control rats (p o 0.05). However, CLG treatment did not alter any
of these parameters. Serum levels of troponin I, the biomarker of
cardiac damage, showed signiﬁcant increase in diabetic rats (p o
0.001) and was restored to normal by CLG treatment (p o 0.05)
(Table 1).
2.2. MAO-A inhibition restored cardiac dysfunction assessed by
electrocardiography and catheterization
ECG analysis was performed to investigate the changes in
electrical activity of the heart. At 8 weeks after the induction of
diabetes, slower heart rate was evident in diabetic rats compared
to vehicle control rats (p o 0.05). Compared to vehicle control,
diabetic rats showed prolongation of QRS interval (p o 0.001), QT
interval (p o 0.01), and QTc interval (p o 0.05), indicating de-
velopment of intraventricular conduction abnormalities. To further
conﬁrm the LV dysfunction, MABP, LVSP, LVEDP, contractility index,
systolic and diastolic durations were measured by cardiac cathe-
terization. Compared to vehicle controls, diabetic rats showed in-
crease in MABP (p o 0.05), systolic duration (p o 0.01), and
diastolic duration (p o 0.05). These changes were normalized
with CLG administration. Diabetic condition also caused signiﬁcant
reduction in contractility index (p o 0.05) (Table 2). Compared to
vehicle control, diabetic rats showed increases in LVSP (p o 0.05)and LVEDP (p o 0.05), whereas (dp/dtmin)/LVSP was decreased
(Fig. 1). However; CLG treatment restored each of these para-
meters to normal.
2.3. MAO-A inhibition attenuates diabetes-induced oxidative stress
Diabetes did not alter the expression of myocardial MAO-A
protein (Fig. 2A). However, a signiﬁcant increase in MAO-A activity
was observed in the myocardium of diabetic rats (p o 0.01)
(Fig. 2B). Further we assessed cardiac levels of the MAO-A sub-
strate NE and its catabolic product DHPG. Higher DHPG/NE ratio
conﬁrms increased MAO-A activity in the heart of diabetic rats
compared to vehicle control rats (Fig. 2C). CLG treatment showed
90% reduction (p o 0.001) in MAO-A activity without altering its
protein expression.
Further, we examined the relationship between MAO-A and
cardiac oxidative stress in the STZ-induced diabetic rats. Lipid
peroxidation, a major marker of oxidative stress, was assessed by
examining cardiac levels of 4-HNE and MDA. Diabetic rats ex-
hibited higher levels of myocardial 4-HNE than the vehicle control
group (p o 0.01) and were restored to normal by CLG treatment
(p o 0.01) (Fig. 3A). HPLC analysis showed that MDA levels were
increased in myocardium of diabetic rats compared to vehicle
controls and this increase was signiﬁcantly reduced by CLG ad-
ministration (p o 0.05) (Fig. 3B).
We next measured the activity of the antioxidant enzyme SOD
in cardiac tissues of control and diabetic rats. An increase in the
SOD activity was observed in the STZ group compared to the
Fig. 3. MAO-A inhibition limits diabetes-induced myocardial oxidative stress. (A) (Left) Immunoﬂuorescence staining for 4-HNE and (right) quantiﬁcation of integrated
optical density (n ¼ 4/group). (B) Quantiﬁcation of myocardial MDA levels by HPLC method (n ¼ 3/group). (C) SOD activity (n ¼ 5–9/group) and (D) UCP3 protein expression
(n ¼ 5/group). All values are given as the mean 7 SE; nnp o 0.01, nnnp o 0.001 vs control group; #p o 0.05, ##p o 0.01 vs STZ group.
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Fig. 4. Clorgyline treatment has no effect on myocardial H2O2-scavenging proteins. (A) Glutathione peroxidase (GPx) activity (n ¼ 5/group). (B) Catalase activity (n ¼ 6–9/
group). (C) Peroxiredoxin-3 (Prx-3) protein expression. Representative Western blot image (left) and densitometric analysis (right; n ¼ 5/group). (D) Prx-5 protein ex-
pression. Representative Western blot image (left) and densitometric analysis (right; n ¼ 6/group). All values are given as the mean 7 SE; *p o 0.05, ***p o 0.001 vs control
group.
P. Umbarkar et al. / Free Radical Biology and Medicine 87 (2015) 263–273 269vehicle control group (p o 0.001). This increase in SOD activity,
which may be a compensatory response to the oxidative stress,
was also reduced in diabetic rats treated with the CLG (p o 0.05)
(Fig. 3C). We also observed a remarkable increase in myocardial
UCP3 protein expression, a marker of mitochondrial uncoupling
and redox stress, in the diabetic group, and CLG treatment was
able to restore the protein levels of UCP3 to normal (Fig. 3D).
Because the antioxidant enzymes catalase, GPx, peroxiredoxin-
3 (Prx-3), and peroxiredoxin-5 (Prx-5) are known to speciﬁcally
scavenge H2O2 in cytoplasm and mitochondria, we further mea-
sured the activity of catalase and GPx and examined the protein
expression of Prx-3 and Prx-5. We observed a decrease in the GPx
activity (Fig. 4A) and Prx-3 protein expression (Fig. 4C) and an
increase in the catalase activity (Fig. 4B) and Prx-5 proteinexpression (Fig. 4D) in hearts of STZ-induced diabetic rats. How-
ever, CLG treatment had no effect on these alterations.
2.4. MAO-A inhibition prevents cardiac apoptosis
We investigated the role of MAO-A in the molecular mechan-
isms involved in diabetes-induced cardiac apoptosis. In particular,
we focused on the expression of Bcl-2 and Bax proteins. Bcl-2 and
Bax are homologous proteins that have opposing effects on cell
survival and death, with Bcl-2 serving to prolong cell survival and
Bax acting as an accelerator of apoptosis [25]. Thus the Bcl-2/Bax
ratio serves as one of the important markers of apoptosis. We
examined the expression of Bcl-2 and Bax by Western blotting.
Diabetic rats showed signiﬁcant decrease (p o 0.05) in Bcl-2/Bax
Fig. 5. MAO-A inhibition prevents diabetes-induced myocardial apoptosis. (A) Bcl-2 and Bax protein expression. Representative western blot image (left) and quantiﬁcation
(right, n ¼ 7/group). (B) Analysis of cytosolic cytochrome c levels. Representative Western blot image (left) and quantiﬁcation (right; n ¼ 3/group). (C) Caspase 9 activity (n
¼ 4–7/group). (D) Caspase 3 activity (n ¼ 5 or 6/group). (E) Examination of cardiac apoptosis using TUNEL staining. Representative TUNEL section shown on left, arrow
indicates TUNEL-positive nucleus, and quantiﬁcation (right; n ¼ 3 or 4/group). All values are given as the mean 7 SE; *p o 0.05, **p o 0.01 vs control group; #p o 0.05, ##p
o 0.01 vs STZ group.
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Fig. 6. MAO-A inhibition attenuates diabetes-induced changes in myocardial histology and cardiac ﬁbrosis. (A) Representative H&E-stained cardiac sections; arrows de-
monstrate (a) separation and (b) degeneration of myocardial ﬁbers. (B) Cardiac ﬁbrosis. Representative Sirius red-stained sections (above), collagen appears red as indicated
by arrows, and quantiﬁcation (below; n ¼ 5/group). All values are given as the mean 7 SE; *p o 0.05 vs control group; #p o 0.05 vs STZ group.
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Bcl-2 and Bax levels were seen to be normalized, resulting in a
signiﬁcantly increased Bcl-2/Bax ratio (p o 0.05) (Fig. 5A).
Previous reports revealed that Bax induces the release of cy-
tochrome c from mitochondria to cytoplasm, whereas Bcl-2 pre-
vents it [26,27]. Further, it is reported that caspases are important
regulators of apoptosis, and the release of cytochrome c from
mitochondria activates caspases, especially caspase 3 [28]. There-
fore, we analyzed the effect of MAO-A inhibition on release of
cytochrome c and activation of caspases implicated in cardiac cell
death.
To detect cytochrome c release, subcellular fractionation of
heart tissues followed by Western blot analysis of cytosolicfraction was carried out. Results showed that cytosolic cytochrome
c levels were increased in the diabetic group compared to vehicle
control (p ¼ 0.07 by one-way ANOVA) (Fig. 5B). Moreover heart of
diabetic rat showed signiﬁcant increase in the activities of caspase
9 (p o 0.01) (Fig. 5C) and caspase 3 (p o 0.05) (Fig. 5D) compared
to vehicle controls. CLG treatment signiﬁcantly reduced all these
adverse phenomena.
In the vehicle control rat hearts, TUNEL-positive nuclei were
seldom identiﬁed, but in diabetic rat hearts, numerous TUNEL-
positive nuclei were observed (p o 0.05). Diabetic rats treated
with CLG showed a signiﬁcant reduction in the number of TUNEL-
positive nuclei compared to untreated diabetic rat (p o 0.05)
(Fig. 5E).
P. Umbarkar et al. / Free Radical Biology and Medicine 87 (2015) 263–2732722.5. Diabetes-induced myocardial morphological changes and car-
diac ﬁbrosis are ameliorated by treatment with clorgyline
H&E staining of the heart tissues showed that, compared with
vehicle control, diabetic hearts displayed structural abnormalities
such as degeneration of cardiac myoﬁbrils, a marked separation of
myocardial ﬁbers from one another, congestion and hemorrhages
in epicardium, and accumulation of polymorphonuclear neu-
trophils. However, structural abnormalities in the hearts of dia-
betic rats were prevented by CLG treatment (Fig. 6A).
Myocardial ﬁbrosis was examined by Sirius red staining. Dia-
betes induced a signiﬁcant increase (p o 0.05) in myocardial in-
terstitial and perivascular collagen deposition compared to vehicle
control. The ﬁbrotic changes in the heart were signiﬁcantly alle-
viated when diabetic rats were treated with CLG (Fig. 6B).3. Discussion
In the current study, we demonstrated that pharmacological
inhibition of MAO-A restored cardiac dysfunction in an animal
model of type I diabetes. This was accompanied by decreased
cardiac oxidative stress, apoptosis, and ﬁbrosis. All these beneﬁcial
effects of MAO-A inhibition were seen despite persistent hy-
perglycemia and hyperlipidemia, thus excluding the possibility of
potential cardioprotective effects due to clorgyline-elicited global
metabolic beneﬁts.
MAOs are important sources of ROS in the heart and MAO-A-
derived ROS play a deleterious role under cardiac duress such as
hearts subjected to hemodynamic overload or I/R injury [9,10]. In
the present study we found that MAO-A activity increases in the
hearts of STZ-induced diabetic rats and administration of the
MAO-A-speciﬁc inhibitor CLG prevented diabetes-induced oxida-
tive stress. We might predict that the reduction in oxidative stress
is due to inhibition of MAO-A-mediated H2O2 production, as we
have excluded the involvement of other H2O2 scavengers such as
catalase, glutathione peroxidase, and peroxiredoxins.
Increased levels of ROS are documented to have a causative
effect on diabetic cardiomyopathy [29,30]. A previous report has
shown that in STZ-induced diabetic rats, ROS leads to cardiac cell
death via a mitochondria-dependent apoptotic pathway [24].
Consistent with this report we observed myocardial apoptosis in
the STZ-induced diabetic rats as evidenced by decreased Bcl-2/Bax
ratio, cytochrome c release, activation of the caspase cascade, and
increased TUNEL-positive nuclei. These observations could be re-
versed by MAO-A inhibition, indicating that MAO-A-derived ROS
trigger myocardial apoptosis via an intrinsic pathway.
Diastolic dysfunction is one of the earliest manifestations in the
progression of diabetic cardiomyopathy [31, 32]. dp/dt, a cardiac
diastolic index, is widely used to assess diastolic function. Because
LVSP was demonstrated to be a hemodynamic determinant of
dp/dtmin, several studies have implemented (dp/dtmin)/LVSP to
evaluate left-ventricular diastolic function more accurately [33–
36]. Thus we selected both dp/dtmin and (dp/dtmin)/LVSP to
determine whether MAO-A inhibition could restore diastolic
function in diabetic rats. STZ-induced diabetic rats developed
diastolic dysfunction as indicated by a signiﬁcant increase in
LVEDP and reduced (dp/dtmin)/LVSP. MAO-A inhibition in turn
restored each of these parameters. Additionally, cardiac ﬁbrosis
has been correlated with diastolic dysfunction [37]. This is in
agreement with our ﬁndings concerning impaired diastolic func-
tion, as was shown in the current study by invasive LVP data. In
STZ-induced diabetic rats, an elevation in myocardial collagen
content was prevented by CLG treatment. This further supports a
beneﬁcial effect of MAO-A inhibition in preventing excess accu-
mulation of extracellular matrix proteins, which may impede LVcontractility. Diabetes also affects electrical activity of the heart
and ECG offers a noninvasive screen to assess these changes
[38,39]. QTc interval, an electrocardiographic parameter, is of
particular clinical signiﬁcance as it is a prominent predictor of
stroke and mortality in patients with diabetes [40,41]. In our
model of type I diabetes, ECG showed QTc prolongation, an ob-
servation that is consistent with previous work [39,42]. CLG
treatment signiﬁcantly reduced this QTc dispersion. All these ob-
servations indicate that increased MAO-A activity contributes to
the development of cardiac contractile dysfunction in diabetic
cardiomyopathy.4. Conclusions
In summary our ﬁndings support MAO-A as an important
source of ROS that contribute to oxidative stress in DCM. Fur-
thermore, prevention of cardiac contractile dysfunction, apoptosis,
and ﬁbrosis by a speciﬁc inhibitor of MAO-A, clorgyline, suggests
that an increase in cardiac MAO-A activity could play a major role
in the progression of DCM and proposes MAO-A as a promising
pharmaceutical target for cardioprotection in diabetes.Authors’ contributions
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